Floatz logo

Herzuma

Recurrent Primary Peritoneal Carcinoma

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

30 Active assets in the Recurrent Primary Peritoneal Carcinoma cohort.

Asset / SponsorPhaseRating
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Olaparib
University of Colorado, Denver
Phase 3BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 3BB
Durvalumab
National Cancer Institute (NCI)
Phase 2BB
Veliparib
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Herzuma is also rated in:

Unresectable Malignant Solid NeoplasmDormant
B
Indicative ·
58 / 100
View asset →
Metastatic Malignant Solid NeoplasmDormant
B
Indicative ·
58 / 100
View asset →
HER2 Gene MutationDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →